Key result
Hirudin anticoagulation during prolonged CPB shows no link between delayed thrombin generation and fibrinopeptide formation.
Why the study?
Does hirudin anticoagulation prevent thrombin-mediated fibrin formation in patients with heparin-induced thrombocytopenia requiring cardiopulmonary bypass?
Case Report
Does hirudin anticoagulation prevent thrombin-mediated fibrin formation in patients with heparin-induced thrombocytopenia requiring cardiopulmonary bypass?
Hirudin may be an effective alternative anticoagulant to prevent thrombin-mediated fibrin formation during cardiopulmonary bypass in patients with heparin-induced thrombocytopenia.
Answers are grounded in this paper and cite their sources.
May support hirudin in HIT during CPB; hypothesis-generating and requires prospective validation before practice change.
Patients with heparin-induced thrombocytopenia urgently requiring surgery with cardiopulmonary bypass (CPB) present a unique management challenge that must be addressed by the use of alternative anticoagulants. Although clinical success with the direct thrombin inhibitor hirudin has been reported, there is sparse information in the literature supporting the efficacy of this drug as an anti-thrombotic to prevent fibrin formation during CPB. In this report, we describe the efficacy of this drug to prevent thrombin-mediated fibrin formation during CPB.
No takes yet. Share an insight, caveat, or question.
Belway et al. (2006) conducted a case report in Heparin-induced thrombocytopenia requiring surgery with cardiopulmonary bypass. Hirudin was evaluated on Thrombin-mediated fibrin formation during cardiopulmonary bypass. Delayed thrombin generation is not associated with fibrinopeptide formation during prolonged cardiopulmonary bypass with hirudin anticoagulation.
Synapse has enriched 10 related papers. Consider them for comparative context: